Aeterna Zentaris (AEZS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock AEZS vs. ASBP, PMN, GDTC, ADAP, CING, TAOX, AYTU, SYBX, LSTA, and TLPHShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Aspire Biopharma (ASBP), Promis Neurosciences (PMN), CytoMed Therapeutics (GDTC), Adaptimmune Therapeutics (ADAP), Cingulate (CING), Synaptogenix (TAOX), Aytu BioPharma (AYTU), Synlogic (SYBX), Lisata Therapeutics (LSTA), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Its Competitors Aspire Biopharma Promis Neurosciences CytoMed Therapeutics Adaptimmune Therapeutics Cingulate Synaptogenix Aytu BioPharma Synlogic Lisata Therapeutics Talphera Aspire Biopharma (NASDAQ:ASBP) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Is ASBP or AEZS more profitable? Aspire Biopharma has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aspire Biopharma's return on equity of 0.00% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A -737.96% Aeterna Zentaris -760.32%-83.45%-45.76% Do insiders and institutionals have more ownership in ASBP or AEZS? 19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 48.0% of Aspire Biopharma shares are owned by company insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, ASBP or AEZS? Aspire Biopharma has higher earnings, but lower revenue than Aeterna Zentaris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/A-$12.54MN/AN/AAeterna Zentaris$2.37M0.00-$16.55M-$14.86N/A Which has more volatility & risk, ASBP or AEZS? Aspire Biopharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Does the media favor ASBP or AEZS? In the previous week, Aspire Biopharma had 3 more articles in the media than Aeterna Zentaris. MarketBeat recorded 3 mentions for Aspire Biopharma and 0 mentions for Aeterna Zentaris. Aeterna Zentaris' average media sentiment score of 0.00 beat Aspire Biopharma's score of -0.06 indicating that Aeterna Zentaris is being referred to more favorably in the news media. Company Overall Sentiment Aspire Biopharma Neutral Aeterna Zentaris Neutral SummaryAspire Biopharma beats Aeterna Zentaris on 6 of the 10 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.52M$856.09M$5.79B$10.40BDividend YieldN/A4.84%5.63%4.60%P/E Ratio-0.211.2380.5826.78Price / SalesN/A26.44534.22123.54Price / CashN/A19.5637.9961.55Price / BookN/A6.7015.776.40Net Income-$16.55M-$4.03M$3.30B$271.80M7 Day PerformanceN/A-1.11%5.36%3.48%1 Month Performance17.11%7.82%8.10%9.90%1 Year Performance-25.47%17.98%81.36%28.44% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/AN/AN/A-27.2%$5.52M$2.37M-0.2120ASBPAspire BiopharmaN/A$0.45+8.1%N/AN/A$22.06MN/A0.00N/ANews CoverageGap UpPMNPromis Neurosciences2.9791 of 5 stars$0.42+1.3%$4.33+922.0%-64.1%$21.97MN/A-2.025Short Interest ↓GDTCCytoMed Therapeutics2.0019 of 5 stars$2.00-6.1%$5.00+149.9%+20.3%$21.89M$69.50K0.00N/APositive NewsADAPAdaptimmune Therapeutics2.077 of 5 stars$0.08+22.8%$1.35+1,552.4%-85.7%$21.68M$178.03M-0.13490News CoverageOptions VolumeGap UpHigh Trading VolumeCINGCingulate2.6127 of 5 stars$3.93+0.5%$26.25+567.9%-31.1%$21.26MN/A-0.9620News CoverageAnalyst RevisionTAOXSynaptogenixN/A$6.03+1.3%N/AN/A$21.05MN/A-0.304AYTUAytu BioPharma3.6368 of 5 stars$2.34+0.4%$10.00+327.4%+1.7%$21.01M$81M-3.25160Positive NewsUpcoming EarningsSYBXSynlogic0.7512 of 5 stars$1.74+5.7%N/A+21.9%$20.36M$10K-21.7580News CoverageShort Interest ↓LSTALisata Therapeutics3.178 of 5 stars$2.30+8.5%$23.50+921.7%-23.6%$20.15M$1M-1.0330Short Interest ↓Gap DownTLPHTalphera1.9002 of 5 stars$0.98flat$5.00+410.2%-9.7%$20.11M$650K-2.4519Gap Down Related Companies and Tools Related Companies ASBP Alternatives PMN Alternatives GDTC Alternatives ADAP Alternatives CING Alternatives TAOX Alternatives AYTU Alternatives SYBX Alternatives LSTA Alternatives TLPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AEZS Stock Alerts